PHAS PhaseBio Pharmaceuticals Inc.

5.26
-0.03  -1%
Previous Close 5.29
Open 5.1
Price To Book 2.14
Market Cap 151,310,906
Shares 28,766,332
Volume 189,180
Short Ratio
Av. Daily Volume 620,008
Stock charts supplied by TradingView

NewsSee all news

  1. PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

    MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies

  2. PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

    PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- PhaseBio

  3. PhaseBio to Present at Stifel 2019 Healthcare Conference

    MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel

  4. PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress

    Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Initiated Registrational Phase

  5. PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019

    MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due 2H 2020.
PB1046
Pulmonary arterial hypertension (PAH)
Phase 2b commencement of dosing announced October 15, 2019. Phase 3 trial to commence 1Q 2020.
PB2452
Reversal agent for ticagrelor

Latest News

  1. PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

    MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies

  2. PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

    PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- PhaseBio

  3. PhaseBio to Present at Stifel 2019 Healthcare Conference

    MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel

  4. PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress

    Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Initiated Registrational Phase

  5. PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019

    MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies

  6. PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

    MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies

  7. PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

    MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel

  8. Pharmacodynamics Evaluation of PhaseBio's Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019

    MALVERN, Pa. and SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel

  9. PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019

    MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies